Effects of dopaminergic antagonists on striatal DOPAC concentrations and alpha-methyl-p-tyrosine-induced decline of dopamine following intrastriatal injections of kainic acid.
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism*; D000818:Animals; D003342:Corpus Striatum / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism; D018492:Dopamine Antagonists; D004347:Drug Interactions; D007267:Injections; D007608:Kainic Acid / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D008781:Methyltyrosines / Q000494:pharmacology*; D010648:Phenylacetates / Q000378:metabolism*; D011759:Pyrrolidines / Q000494:pharmacology*; D051381:Rats; D013997:Time Factors
D018492:Dopamine Antagonists; D008781:Methyltyrosines; D010648:Phenylacetates; D011759:Pyrrolidines; D015102:3,4-Dihydroxyphenylacetic Acid; D007608:Kainic Acid; D004298:Dopamine